Pharmacologic approaches to life-threatening asthma

Area of Science:

• Pulmonology
• Critical Care Medicine
• Pharmacology

Background:

• Asthma mortality has decreased, but near-fatal events remain common, requiring intensive care.
• Standard treatments for severe asthma include systemic corticosteroids and inhaled beta-agonists.
• Significant knowledge gaps exist regarding optimal therapies for refractory or near-fatal asthma.

Purpose of the Study:

• To review pharmacologic approaches for life-threatening asthma.
• To evaluate current guideline recommendations and their scientific basis.
• To identify gaps in knowledge for refractory acute or near-fatal asthma treatment.

Main Methods:

• Review of current guideline recommendations for severe asthma.
• Analysis of the scientific basis for existing asthma treatment guidelines.
• Identification of areas with limited evidence in critical asthma care.

Main Results:

• Standard therapies are effective for many, but optimal treatments for non-responders are debated.
• Evidence is limited for adjunctive therapies like magnesium, aminophylline, and helium-oxygen.
• Understanding of inhaled beta-agonist delivery in ventilated patients has improved.

Conclusions:

• Variability in critical asthma care practice reflects limited evidence.
• Further research is needed to address knowledge gaps in managing severe and near-fatal asthma.
• Optimizing pharmacologic strategies is crucial for improving outcomes in critical asthma cases.